An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: Various Advanced Cancer
• Intervention / Treatment: Other: Placebo; Biological: Nivolumab

• Study Type: Interventional
• Enrollment (Actual): 709
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Viedma, Argentina, 8500
    • Local Institution - 0102
  • Buenos Aires
    • Berazategui, Buenos Aires, Argentina, 1880
      • Local Institution - 0021
    • Capital Federal, Buenos Aires, Argentina, 1426
      • Local Institution - 0090
    • Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, 1181
      • Local Institution - 0089
    • Ciudad Autónoma de BuenosAires, Buenos Aires, Argentina, C1280AEB
      • Local Institution - 0022
  • Tucumán Province
    • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
      • Local Institution - 0020
• Australia
  • New South Wales
    • Liverpool, New South Wales, Australia, 2170
      • Local Institution - 0048
    • St Leonards, New South Wales, Australia, 2065
      • Local Institution - 0047
    • Waratah, New South Wales, Australia, 2298
      • Local Institution - 0046
  • South Australia
    • Elizabeth Vale, South Australia, Australia, 5112
      • Local Institution - 0050
  • Victoria
    • Frankston, Victoria, Australia, 3199
      • Local Institution - 0184
  • Western Australia
    • Perth, Western Australia, Australia, 6150
      • Local Institution - 0175
• Austria
  • Linz, Austria, 4010
    • Local Institution - 0133
  • Salzburg, Austria, 5020
    • Local Institution - 0136
  • Vienna, Austria, 1090
    • Local Institution - 0132
  • Vienna, Austria, 1090
    • Local Institution - 0183
• Belgium
  • Hasselt, Belgium, 3500
    • Local Institution - 0029
  • Liège, Belgium, 4000
    • Local Institution - 0027
• Brazil
  • Rio de Janeiro, Brazil, 20231-050
    • Local Institution - 0231
  • São Paulo, Brazil, 04014-002
    • Local Institution - 0100
  • Rio Grande do Sul
    • Ijuí, Rio Grande do Sul, Brazil, 98700-000
      • Local Institution - 0071
    • Porto Alegre, Rio Grande do Sul, Brazil, 90610000
      • Local Institution - 0072
  • São Paulo
    • Barretos, São Paulo, Brazil, 14780-070
      • Local Institution - 0070
    • Cerqueira César, São Paulo, Brazil, 01246-000
      • Local Institution - 0073
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Local Institution - 0139
  • Quebec
    • Montreal, Quebec, Canada, H4A 3J1
      • Local Institution - 0109
    • Montreal, Quebec, Canada, H2X 0A9
      • Local Institution - 0101
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • Local Institution - 0112
• Chile
  • Temuco, Chile, 4810297
    • Local Institution - 0137
  • Región de Valparaíso
    • Viña del Mar, Región de Valparaíso, Chile, 2540364
      • Local Institution - 0038
  • Santiago Metropolitan
    • Santiago, Santiago Metropolitan, Chile
      • Local Institution - 0099
• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100001
      • Local Institution - 0191
    • Beijing, Beijing Municipality, China, 100034
      • Local Institution - 0206
    • Beijing, Beijing Municipality, China, 100050
      • Local Institution - 0192
  • Chongqing Municipality
    • Chongqing, Chongqing Municipality, China, 400030
      • Local Institution - 0210
  • Fujian
    • Fuzhou, Fujian, China, 350001
      • Local Institution - 0198
  • Guangdong
    • Guangzhou, Guangdong, China, 510230
      • Local Institution - 0222
    • Guangzhou, Guangdong, China, 510288
      • Local Institution - 0203
  • Guangxi
    • Nanning, Guangxi, China, 530021
      • Local Institution - 0227
  • Hubei
    • Wuhan, Hubei, China, 430030
      • Local Institution - 0196
  • Jiangsu
    • Nanjing, Jiangsu, China, 210008
      • Local Institution - 0220
    • Nanjing, Jiangsu, China, 210029
      • Local Institution - 0204
  • Jiangxi
    • Nanchang, Jiangxi, China, 330006
      • Local Institution - 0223
  • Shan3xi
    • Xi'an, Shan3xi, China, 710061
      • Local Institution
  • Shandong
    • Yantai, Shandong, China, 264000
      • Local Institution - 0212
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200032
      • Local Institution - 0193
    • Shanghai, Shanghai Municipality, China, 200032
      • Local Institution - 0202
    • Shanghai, Shanghai Municipality, China, 200040
      • Local Institution - 0199
    • Shanghai, Shanghai Municipality, China, 200040
      • Local Institution - 0217
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Local Institution - 0229
    • Chengdu, Sichuan, China, 610072
      • Local Institution - 0219
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310009
      • Local Institution - 0221
    • Hangzhou, Zhejiang, China, 310014
      • Local Institution - 0195
    • Wenzhou, Zhejiang, China, 32500
      • Local Institution - 0230
• Colombia
  • Bogotá, Colombia
    • Local Institution - 0092
  • Floridablanca, Colombia, 681004
    • Local Institution - 0093
  • Medellín, Colombia, 050034
    • Local Institution - 0091
• Denmark
  • Aalborg, Denmark, 9100
    • Local Institution - 0108
  • Aarhus N, Denmark, 8200
    • Local Institution - 0106
  • Copenhagen, Denmark, 2100
    • Local Institution - 0107
• France
  • Clermont-Ferrand, France, 63000
    • Local Institution - 0233
  • La Roche-sur-Yon, France, 85000
    • Local Institution - 0115
  • Marseille, France, 13273
    • Local Institution - 0080
  • Paris, France, 75475
    • Local Institution - 0081
  • Strasbourg, France, 67200
    • Local Institution - 0113
  • Suresnes, France, 92151
    • Local Institution - 0097
  • Villejuif, France, 94800
    • Local Institution - 0098
• Germany
  • Chemnitz, Germany, 09130
    • Local Institution - 0131
  • Essen, Germany, 45136
    • Local Institution - 0125
  • Greifswald, Germany, 17475
    • Local Institution - 0127
  • Hamburg, Germany, 20246
    • Local Institution - 0126
  • Heidelberg, Germany, 69126
    • Local Institution - 0124
  • Jena, Germany, 07747
    • Local Institution - 0123
  • Marburg, Germany, 35043
    • Local Institution - 0188
  • Munich, Germany, 81675
    • Local Institution - 0122
  • Münster, Germany, 48149
    • Local Institution - 0128
  • Nuremberg, Germany, 90419
    • Local Institution - 0185
  • Regensburg, Germany, 93053
    • Local Institution - 0130
  • Stuttgart, Germany, 70174
    • Local Institution - 0129
• Greece
  • Athens, Greece, 115 28
    • Local Institution - 0110
  • Thessaloniki, Greece, 54007
    • Local Institution - 0111
• Ireland
  • Dublin, Ireland
    • Local Institution - 0052
  • CORK
    • Wilton, CORK, Ireland
      • Local Institution - 0054
• Israel
  • Haifa, Israel, 3109601
    • Local Institution - 0118
  • Jerusalem, Israel, 91120
    • Local Institution - 0121
  • Ramat Gan, Israel, 5262100
    • Local Institution - 0120
  • Ẕerifin, Israel, 70300
    • Local Institution - 0119
• Italy
  • Arezzo, Italy, 52100
    • Local Institution - 0088
  • Bergamo, Italy, 24127
    • Local Institution - 0197
  • Milan, Italy, 20133
    • Local Institution - 0082
  • Pisa, Italy, 56126
    • Local Institution - 0084
  • Reggio Emilia, Italy, 42100
    • Local Institution - 0189
  • Roma, Italy, 00144
    • Local Institution - 0085
  • Roma, Italy, 00152
    • Local Institution - 0086
  • Siena, Italy, 53100
    • Local Institution - 0083
• Japan
  • Chiba, Japan, 260-8717
    • Local Institution - 0143
  • Osaka, Japan, 5418567
    • Local Institution - 0164
  • Akita
    • Akita, Akita, Japan, 0108543
      • Local Institution - 0142
  • Aomori
    • Hirosaki, Aomori, Japan, 0368563
      • Local Institution - 0144
  • Fukuoka
    • Fukuoka, Fukuoka, Japan, 8128582
      • Local Institution - 0162
  • Hokkaido
    • Sapporo, Hokkaido, Japan, 060-8543
      • Local Institution - 0160
    • Sapporo, Hokkaido, Japan, 0608648
      • Local Institution - 0161
  • Ibaraki
    • Tsukuba, Ibaraki, Japan, 3058576
      • Local Institution - 0148
  • Nagasaki
    • Nagasaki, Nagasaki, Japan, 8528501
      • Local Institution - 0163
  • Niigata
    • Niigata, Niigata, Japan, 9518520
      • Local Institution - 0150
  • Okayama-ken
    • Okayama, Okayama-ken, Japan, 700-8558
      • Local Institution - 0141
  • Osaka
    • Sayama, Osaka, Japan, 589-8511
      • Local Institution - 0149
  • Shizuoka
    • Hamamatasu, Shizuoka, Japan, 431-3192
      • Local Institution - 0151
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 1138603
      • Local Institution - 0146
    • Shinjuku-Ku, Tokyo, Japan, 1608582
      • Local Institution - 0145
    • Shinjuku-ku, Tokyo, Japan, 1628666
      • Local Institution - 0147
• Mexico
  • México, Mexico, 06700
    • Local Institution - 0116
  • México, Mexico, 14080
    • Local Institution - 0039
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44270
      • Local Institution - 0035
  • Mexico City
    • Df, Mexico City, Mexico, 06720
      • Local Institution - 0138
    • Mexico City, Mexico City, Mexico, 14080
      • Local Institution - 0034
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64460
      • Local Institution - 0032
• Netherlands
  • Maastrict, Netherlands, 6229 HX
    • Local Institution - 0068
  • Nijmegen, Netherlands, 6500 HB
    • Local Institution - 0041
  • North Holland
    • Amsterdam, North Holland, Netherlands, 1081 HV
      • Local Institution - 0069
• Peru
  • Lima, Peru, Lima 41
    • Local Institution - 0043
• Poland
  • Gdansk, Poland, 80-214
    • Local Institution - 0055
  • Lodz, Poland, 93-513
    • Local Institution - 0057
  • Warsaw, Poland, 02-797
    • Local Institution - 0187
  • Wroclaw, Poland, 50-556
    • Local Institution - 0058
  • Wroclaw, Poland, 53-413
    • Local Institution - 0186
• Romania
  • Bucharest, Romania, 021389
    • Local Institution - 0182
  • Craiova, Romania, 200347
    • Local Institution - 0096
  • Floreşti, Romania, 407280
    • Local Institution - 0078
  • Timisoara, Timis, Romania, 300239
    • Local Institution - 0181
• Russia
  • Moscow, Russia, 125284
    • Local Institution - 0140
  • Saint Petersburg, Russia, 197758
    • Local Institution - 0031
• South Korea
  • Seongnam-si, South Korea, 13620
    • Local Institution - 0155
  • Seoul, South Korea, 03722
    • Local Institution - 0154
  • Seoul, South Korea, 05505
    • Local Institution - 0152
  • Seoul, South Korea, 06351
    • Local Institution - 0156
• Spain
  • Badalona-barcelona, Spain, 08916
    • Local Institution - 0067
  • Barcelona, Spain, 08035
    • Local Institution - 0066
  • Madrid, Spain, 28007
    • Local Institution - 0064
  • Madrid, Spain, 28034
    • Local Institution - 0062
  • Madrid, Spain, 28041
    • Local Institution - 0063
  • Santander, Spain, 39008
    • Local Institution - 0232
  • Seville, Spain, 41013
    • Local Institution - 0065
• Sweden
  • Lund, Sweden, 221 85
    • Local Institution - 0105
• Switzerland
  • Basel, Switzerland, 4031
    • Local Institution - 0134
  • Zurich, Switzerland, 8038
    • Local Institution - 0135
• Taiwan
  • Kaohsiung City, Taiwan, 807
    • Local Institution - 0158
  • Taichung, Taiwan, 404
    • Local Institution - 0159
  • Taipei, Taiwan, 100
    • Local Institution - 0153
• United Kingdom
  • London, United Kingdom, SE1 9RT
    • Local Institution - 0036
  • London, United Kingdom, SW3 6JJ
    • Local Institution - 0114
  • Greater Manchester
    • Manchester, Greater Manchester, United Kingdom, M20 4BX
      • Local Institution - 0025
  • Midlothian
    • Edinburgh, Midlothian, United Kingdom, EH4 2XU
      • Local Institution - 0076
  • Surrey
    • Sutton, Surrey, United Kingdom, SM2 5PT
      • Local Institution - 0024
  • Yorkshire
    • Sheffield, Yorkshire, United Kingdom, S10 2SJ
      • Local Institution - 0059
• United States
  • Alaska
    • Anchorage, Alaska, United States, 99503
      • Alaska Urological Institute dba Alaska Clinical Research Center
  • Arizona
    • Tucson, Arizona, United States, 85704
      • Local Institution - 0179
  • California
    • Clovis, California, United States, 93611
      • Local Institution - 0061
    • Sacramento, California, United States, 95817
      • Local Institution - 0172
    • San Francisco, California, United States, 94115
      • Local Institution - 0005
  • Colorado
    • Lakewood, Colorado, United States, 80228
      • Local Institution - 0178
  • Florida
    • Gainesville, Florida, United States, 32610
      • Local Institution - 0167
    • Miami Beach, Florida, United States, 33140
      • Local Institution - 0030
    • Tampa, Florida, United States, 33612
      • Local Institution - 0008
  • Illinois
    • Maywood, Illinois, United States, 60153
      • Local Institution - 0168
  • Indiana
    • Fort Wayne, Indiana, United States, 46804
      • Local Institution - 0094
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
      • Local Institution - 0171
  • Michigan
    • Grand Rapids, Michigan, United States, 49503
      • Local Institution - 0173
  • Minnesota
    • Burnsville, Minnesota, United States, 55337
      • Local Institution - 0051
    • Rochester, Minnesota, United States, 55905
      • Local Institution - 0004
  • Nebraska
    • Omaha, Nebraska, United States, 68130
      • Local Institution - 0003
  • Nevada
    • Las Vegas, Nevada, United States, 89148
      • Local Institution - 0177
  • New York
    • Albany, New York, United States, 12208
      • Local Institution - 0176
    • Buffalo, New York, United States, 14263
      • Local Institution - 0157
    • Mineola, New York, United States, 11501
      • Local Institution - 0007
    • New York, New York, United States, 10021
      • Local Institution - 0001
    • New York, New York, United States, 10029
      • Local Institution - 0006
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599-7305
      • Local Institution - 0166
    • Durham, North Carolina, United States, 27708
      • Local Institution
  • Oregon
    • Portland, Oregon, United States, 97213
      • Local Institution - 0044
    • Portland, Oregon, United States, 97239
      • Local Institution - 0010
    • Tigard, Oregon, United States, 97223
      • Local Institution - 0180
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18103
      • Local Institution - 0074
    • Pittsburgh, Pennsylvania, United States, 15212
      • Local Institution - 0011
    • Pittsburgh, Pennsylvania, United States, 15232
      • Local Institution - 0040
  • South Carolina
    • Myrtle Beach, South Carolina, United States, 29572
      • Local Institution - 0169
  • Tennessee
    • Chattanooga, Tennessee, United States, 37404
      • Local Institution - 0009
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Local Institution - 0234

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Must have had invasive urothelial cancer at high risk of recurrence originating in the bladder, ureter, or renal pelvis
• Must have had radical surgical resection (e.g. radical cystectomy), performed within the last 120 days
• Must have disease free status as determined by imaging within 4 weeks of dosing
• Tumor tissue must be provided for biomarker analysis
• Patients who have not received prior neoadjuvant cisplatin chemotherapy must be ineligible for or refuse cisplatin-based adjuvant chemotherapy

Exclusion Criteria:

• Partial bladder or partial kidney removal (eg, partial cystectomy or partial nephrectomy)
• Secondary Treatment (eg, adjuvant systemic chemotherapy for bladder cancer) following surgical removal of bladder cancer
• Subjects with active, known or suspected autoimmune disease
• Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
• Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 day of study drug administration
• Positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nivolumab; Nivolumab dose as specified	Biological: Nivolumab
Placebo Comparator: Placebo; Placebo dose as specified	Other: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease Free Survival (DFS)	The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.	approximately up to 48 months
Disease Free Survival (DFS) in PD-L1 Expression ≥ 1% Population	The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.	approximately up to 48 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Non-Urothelial Tract Recurrence Free Survival	The time between the date of randomization and the date of first documented recurrence (local non-urothelial tract or distant), or death due to any cause, whichever occurs first.	up to 53 months
Non-Urothelial Tract Recurrence Free Survival in PD-L1 Expression ≥ 1% Population	The time between the date of randomization and the date of first documented recurrence (local non-urothelial tract or distant), or death due to any cause, whichever occurs first.	up to 53 months
Overall Survival	the time from randomization to the date of death from any cause.	on going
Overall Survival in Participants With PD-L1 Expression ≥ 1%	the time from randomization to the date of death from any cause.	on going
Disease Specific Survival	the time from randomization to the date of death due to disease (urothelial cancer).	on going
Disease Specific Survival in Participants With PD-L1 Expression ≥ 1%	the time from randomization to the date of death due to disease (urothelial cancer).	on going

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb
• Collaborators: Ono Pharmaceutical Co. Ltd
• Investigators: Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

General Publications

• Galsky MD, Bajorin DF, Tomita Y, Ye D, Agerbaek M, Enting D, Peer A, Milowsky M, Kobayashi K, Grimm MO, Stenner F, David JM, Li J, Chasalow SD, Nasroulah F, Apfel A, Unsal-Kacmaz K, Necchi A. Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. Nat Med. 2025 Sep;31(9):3062-3073. doi: 10.1038/s41591-025-03802-8. Epub 2025 Aug 7.
• Geynisman DM, Chepynoga K, Yates G, Tate A, Kurt M, Patel MY, Teitsson S, Mitra S, Mamtani R. Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial. Clin Genitourin Cancer. 2025 Jun;23(3):102335. doi: 10.1016/j.clgc.2025.102335. Epub 2025 Mar 17.
• Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J Clin Oncol. 2025 Jan;43(1):15-21. doi: 10.1200/JCO.24.00340. Epub 2024 Oct 11.
• Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Antonio JN Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary. Future Oncol. 2023 Feb;19(6):413-426. doi: 10.2217/fon-2022-1294. Epub 2023 Mar 15.
• Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF. Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. Eur Urol Oncol. 2022 Oct;5(5):553-563. doi: 10.1016/j.euo.2022.02.003. Epub 2022 Mar 11.
• Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.

Helpful Links

• BMS Clinical Trial Information
• BMS Clinical Trial Patient Recruiting

Study record dates

Study Major Dates

• Study Start (Actual): March 22, 2016
• Primary Completion (Actual): July 17, 2020
• Study Completion (Estimated): May 27, 2027

Study Registration Dates

• First Submitted: December 14, 2015
• First Submitted That Met QC Criteria: December 15, 2015
• First Posted (Estimated): December 16, 2015

Study Record Updates

• Last Update Posted (Estimated): October 16, 2025
• Last Update Submitted That Met QC Criteria: October 7, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Amino Acids, Peptides, and Proteins; Proteins; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Nivolumab
• Other Study ID Numbers: CA209-274; 2014-003626-40 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No